Xenon Pharmaceuticals Inc. (Nasdaq: XENE) based in Vancouver, British Columbia and Boston, MA, disclosed today that it will have multiple presentations at the upcoming American Academy of Neurology Annual Meeting in April 2026 in Chicago, Illinois. The company will present five abstracts, which encompass a Late-breaking Science oral and poster presentation unveiling the topline results from the Phase 3 X-TOLE2 study for azetukalner in focal onset seizures (FOS). Additionally, a poster presentation on the extended 48-month azetukalner data from the X-TOLE open label extension study will be featured. During the event, Xenon will provide real-world data that sheds light on unmet needs in epilepsy, including insights from patients and clinicians regarding the challenges of antiseizure medication titration and the influence of comorbidities in epilepsy. Furthermore, the company will present data on its preclinical Na V 1.1 program focused on Dravet syndrome.